Lercapress

Lercanidipine Hydrochloride, the active ingredient in Lercapress, is a calcium channel blocker presented as an oral tablet for oral use. It treats hypertension in adult patients by relaxing vascular smooth muscle and lowering blood pressure.

GNH USA supplies Lercapress as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercapress is a calcium‑channel‑blocking antihypertensive used to manage elevated blood pressure.

Hypertension: lowers systolic and diastolic pressure, helping to reduce the risk of stroke, myocardial infarction and other cardiovascular complications.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Headache - Flushing - Peripheral edema - Dizziness - Tachycardia - Fatigue

Serious or Rare Side Effects: - Severe hypotension - Myocardial infarction - Angioedema - Hepatic injury - Life‑threatening arrhythmias

Patients should be monitored for blood‑pressure response and potential adverse events. - Blood pressure monitoring: check regularly after initiation and dose adjustments. - Hepatic impairment: use with caution; dose may need adjustment. - Elderly patients: start at lower dose and titrate slowly. - Concomitant antihypertensives: assess for additive hypotensive effect. - Hypersensitivity: discontinue if allergic reaction occurs. - Store at below 25°C: keep in the original pack, protect from moisture.

Lercapress can interact with several drug classes; clinical judgment is required.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels. - Other potent antihypertensives: risk of excessive hypotension. - Grapefruit juice: can elevate drug exposure.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Diuretics: may enhance electrolyte disturbances. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may attenuate blood‑pressure‑lowering effect.